Haleos Labs Ltd

Stage 3 · Topping · week 4

As of 16 Oct 2026, Haleos Labs is in Stage 3 — topping, where an uptrend loses steam, in week 4 (since 24 Sep 2026). It closed at ₹1,532, above its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. More about the company

₹1,532.4
-1.71% today
₹463 Cr · Micro cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is HALEOSLABS early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
—
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 4
1w13w26w
Week 4 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
8.2%
200 DMA: ₹1,415.7 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.76x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↗ ⇈
Accelerating · MA20 +3.0% vs MA50 -0.9% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+1.6%
3M
-3.0%
6M
+18.5%
YTD
+25.6%
1Y
—
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2025-11-17 → 2026-10-16
S? 42w
2025-11-172026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 2w → S3 3w current
Total tracked: 48 weeks across 3 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-09-08
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 4 · Vol 0.76x
2026-10-15S3
Wk 3 · Vol 0.61x
2026-10-14S3
Wk 3 · Vol 1.05x
2026-10-13S3
Wk 3 · Vol 1.44x
2026-10-12S3
Wk 3 · Vol 0.64x
2026-10-09S3
Wk 3 · Vol 1.03x
2026-10-08S3
Wk 2 · Vol 0.49x
2026-10-07S3
Wk 2 · Vol 1.12x
2026-10-06S3
Wk 2 · Vol 0.90x
2026-10-05S3
Wk 2 · Vol 2.77x
2026-10-01S3
Wk 2 · Vol 1.08x
2026-09-30S3
Wk 1 · Vol 0.95x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹1,494.2
200 DMA
₹1,415.7
52W High
—
52W Low
—
5D Low
₹1,532.4
Resistance levels (recent highs)
20d High
₹1,587.8
60d High
₹1,589
120d High
₹1,690.1
250d High
—
Next resistance
+3.6%
to 20d High
Ask the Market AI about HALEOSLABSAsk →
P/E (TTM)
24.8
Forward —
Earnings Growth (YoY)
+21.1%
Revenue +12.0%
Dividend Yield
0.09%
P/B 2.4
About this companyHealth Care· Pharmaceuticals

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.